Plus Therapeutics Shares Jump After FDA Accepts Name of Lead Tumor Treatment Candidate

MT Newswires Live

2025/03/21

Plus Therapeutics (PSTV) shares jumped nearly 183% in recent trading Thursday after the company said the US Food and Drug Administration conditionally accepted the proprietary name for its lead tumor therapy candidate.

The medicine will be known as Reyobiq and will be subject to a proprietary name review once a new drug application is submitted, Plus Therapeutics said.

The company is developing Reyobiq as an injectable radiotherapy to treat central nervous system tumors.

Price: 1.45, Change: +0.93, Percent Change: +182.78

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2521446719"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2521446719\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2521446719?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-21 01:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2521446719","market":"hk","top_or_hot":-1,"title":"Plus Therapeutics Shares Jump After FDA Accepts Name of Lead Tumor Treatment Candidate","media":"MT Newswires Live","content":"<html><body><p> Plus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (PSTV) shares jumped nearly 183% in recent trading Thursday after the company said the US Food and Drug Administration conditionally accepted the proprietary name for its lead tumor therapy candidate.</p><p>The medicine will be known as Reyobiq and will be subject to a proprietary name review once a new drug application is submitted, Plus Therapeutics said.</p><p>The company is developing Reyobiq as an injectable radiotherapy to treat central nervous system tumors.</p><p>Price: 1.45, Change: +0.93, Percent Change: +182.78</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Plus Therapeutics Shares Jump After FDA Accepts Name of Lead Tumor Treatment Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPlus Therapeutics Shares Jump After FDA Accepts Name of Lead Tumor Treatment Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-21 01:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Plus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (PSTV) shares jumped nearly 183% in recent trading Thursday after the company said the US Food and Drug Administration conditionally accepted the proprietary name for its lead tumor therapy candidate.</p><p>The medicine will be known as Reyobiq and will be subject to a proprietary name review once a new drug application is submitted, Plus Therapeutics said.</p><p>The company is developing Reyobiq as an injectable radiotherapy to treat central nervous system tumors.</p><p>Price: 1.45, Change: +0.93, Percent Change: +182.78</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2521446719","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2521446719","pubTimestamp":1742493124,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Plus Therapeutics  shares jumped nearly 183% in recent trading Thursday after the company said the US Food and Drug Administration conditionally accepted the proprietary name for its lead tumor therapy candidate.The medicine will be known as Reyobiq and will be subject to a proprietary name review once a new drug application is submitted, Plus Therapeutics said.The company is developing Reyobiq as an injectable radiotherapy to treat central nervous system tumors.Price: 1.45, Change: +0.93, Percent Change: +182.78","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LENZ":"Therapeutics","PSTV":"Plus Therapeutics, Inc."},"translate_title":"FDA接受主要肿瘤治疗候选药物名称后，Plus Therapeutics股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PSTV":0.9,"LENZ":1},"content_text":"Plus Therapeutics (PSTV) shares jumped nearly 183% in recent trading Thursday after the company said the US Food and Drug Administration conditionally accepted the proprietary name for its lead tumor therapy candidate.The medicine will be known as Reyobiq and will be subject to a proprietary name review once a new drug application is submitted, Plus Therapeutics said.The company is developing Reyobiq as an injectable radiotherapy to treat central nervous system tumors.Price: 1.45, Change: +0.93, Percent Change: +182.78","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}